Esteller and colleagues detected aberrant MGMT promoter methylation in 40% of the gliomas and defined it as a decisive, independent, prognostic factor associated with regression of the tumor and overall survival in patients treated with radiotherapy and alkylating agent bis-chloroethyl nitrosourea (BCNU) [12,13]. The gene discussed is MGMT; the disease is central nervous system cancer.